Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 7/20 | 0.35 |
| ▸ | DRD3 | P35462 | 6/20 | 0.35 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | CALML3 | P27482 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5232566 | 0.88 | SIGMAR1 (0.43) | MAOASIGMAR1GRM2DRD4DRD3 | |
| SCHEMBL5237150 | 0.87 | MAOA (0.37) | MAOASIGMAR1GRM2DRD4DRD3 | |
| SCHEMBL5236775 | 0.84 | MAOA (0.39) | MAOASIGMAR1GRM2DRD4DRD3 | |
| SCHEMBL5233293 | 0.84 | CALML3 (0.48) | MAOASIGMAR1GRM2DRD4DRD3 | |
| SCHEMBL4011956 | 0.84 | GRM2 (0.42) | SIGMAR1GRM2DRD4DRD3DRD2 | |
| SCHEMBL5833839 | 0.84 | CALML3 (0.48) | MAOASIGMAR1GRM2DRD4DRD3 | |
| SCHEMBL5233354 | 0.82 | MAOA (0.53) | MAOAMAOB | |
| SCHEMBL5235521 | 0.82 | SIGMAR1 (0.38) | MAOASIGMAR1GRM2DRD4DRD3 | |
| SCHEMBL4017354 | 0.81 | SIGMAR1 (0.40) | MAOASIGMAR1GRM2DRD4DRD3 | |
| SCHEMBL4013743 | 0.81 | MAOA (0.54) | MAOASIGMAR1HTR6MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1286998-B2 | OXAZOLIDINONE DERIVATIVES WITH ANTIBIOTIC ACTIVITY | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | EP | disclosed |
| US-7141583-B2 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2006-11-28 | — | — | US | disclosed |
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | ASTRAZENECA AB (SE) | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216373-A1 | Oxazolidinone derivatives with antibiotic activity | STS, SULT1E1, OXA1L | MAOA 2239/4885SIGMAR1 610/4885GRM2 4159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.